We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of BIOT yet.

BIOT Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q1 2023, worth a combined $0 — down 100% from $226M a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of BIOT and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $23.1M sold.

  • 0 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q1 2023, down from 68 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Class A Ordinary Shares stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q1 2023 and 68 closed out, a net change of -68 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q1 2023 was Glazer Capital LLC, an estimated $23.1M sold.

Based on aggregated 13F filings for Q1 2023.